Bandyopadhyay S, Das S, Samajdar SS, Joshi SR
Exposures at the no observed adverse effect level in all species were subclinical or only slightly higher than the plasma AUC at the maximum recommended human dose
But on a GLP-1 drug, that effect can backfire
Funding This work was supported by the Health Special Project fund of PLA (21BJZ43)
Patient Education and Partnership We know the best results come from informed decisions, good compliance with treatment, and awareness of the risks
Whether this is because of the limit of detection of the neuroprotection assays, or because the semaglutide-induced neuroprotective effects were already maximal, needs to be investigated further